甲磺酸阿帕替尼治疗转移性结直肠癌的临床观察  

Clinical observation of apatinib in the treatment of metastatic colorectal cancer

作　　者：陈竹 刘艳[1] 高丽花[1] 陈不尤[2] 唐爱华[3] 刘军[1] CHEN Zhu;LIU Yan;GAO Li-hua;CHEN Bu-you;TANG Ai-hua;LIU Jun(Department of Chemotherapy,the Affiliated Hospital of Nantong University,Nantong 226001,China;Department of Radiotherapy,the Affiliated Hospital of Nantong University,Nantong 226001,China;Department of Pediatrics,the Affiliated Hospital of Nantong University, Nantong 226001, China)

机构地区：[1]南通大学附属医院肿瘤化疗科,江苏南通226001 [2]南通大学附属医院肿瘤放疗科,江苏南通226001 [3]南通大学附属医院儿内科,江苏南通226001

出　　处：《基础医学与临床》2021年第12期1802-1806,共5页Basic and Clinical Medicine

基　　金：南通市科技计划项目(MS12017017-6)。

摘　　要：目的评价含甲磺酸阿帕替尼方案治疗转移性结直肠癌(mCRC)的疗效和安全性。方法回顾性分析65例含甲磺酸阿帕替尼方案治疗的mCRC患者临床资料,评估影响患者近期有效率、无进展生存时间(PFS)和不良反应等因素。结果63例可评估疗效患者疾病控制率为69.9%。一线、二线和三线及以上治疗患者的中位PFS分别为9.3个月、5.8个月和3.3个月(P<0.001)。三线及以上治疗患者中阿帕替尼组和阿帕替尼联合化疗组PFS分别为2.9个月和3.3个月。肝转移患者治疗前后血清胆碱酯酶和白蛋白浓度无明显差异。不良反应主要为1~2级高血压、蛋白尿、骨髓抑制和手足综合征。结论阿帕替尼是mCRC的有效治疗方案,对肝脏储备功能影响小,毒性可控。Objective To evaluate the efficacy and safety of apatinib in the treatment of metastatic colorectal cancer(mCRC).Methods Sixty-five patients with mCRC treated with apatinib were enrolled in this study for retrospective analysis.The factors affecting the recent effective,progression-free survival(PFS)and adverse reactions were evaluated.Results The disease control rate in 63 evaluable patients was 69.9%.The median PFS for patients received first-line,second-line,and third-line and above apatinib treatment were 9.3 months,5.8 months,and 3.3 months,respectively(P<0.001).The PFS in the apatinib group and the apatinib/chemotherapy combination group in the third-line and above treatment were 2.9 months and 3.3 months,respectively.There was no significant difference in serum cholinesterase and albumin concentrations between patients with liver metastasis before and after treatment.Adverse reactions were mainly grade 1 to 2 hypertension,proteinuria,myelosuppression and hand-foot syndrome.Conclusions Apatinib is an effective treatment with controllable toxicity for mCRC,which has mild adverse effect on liver reserve function.

关 键 词：肠道肿瘤 甲磺酸阿帕替尼 临床疗效 安全性 

分 类 号：R73[医药卫生—肿瘤]